Author

Elyssa Ott 1

1 Janssen Research & Development, LLC, Spring House, United States of America

A POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN?S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 CLINICAL TRIAL PROGRAMS

Subrata Ghosh, Bruce E. Sands, Willem de Villiers, Elyssa Ott, Christopher Gasink, Yinghua Lang, Philippe Szapary, Douglas Jacobstein, Brian G. Feagan

LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS

Subrata Ghosh, Scott Lee, Remo Panaccione, Elyssa Ott, Christopher Gasink, Ye Miao, Colleen W. Marano, Edward V. Loftus

SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS

Silvio Danese, Millie Long, Elyssa Ott, Christopher Gasink, Thomas Baker, Ye Miao, Ilia Tikhonov, Proton Rahman, Edward V. Loftus, Bruce Strober

Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results from Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis

Subrata Ghosh, Bruce E. Sands, Christopher D. O'Brien, Ilia Tikhonov, Yiying Zhou, Sheri Volger, Colleen W. Marano, Elyssa Ott, Christopher Gasink, William Sandborn, Silvio Danese

SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (≥60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS

Subrata Ghosh, Elyssa Ott, Christopher Gasink, Ye Miao, Colleen W. Marano, John Lynch, Maria T. Abreu, Aline Charabaty

Item 1 - 5 / 5
1